U.S. patent application number 14/899607 was filed with the patent office on 2016-10-13 for novel fat accumulation inhibitory peptide and pharmaceutical composition for preventing or treating obesity containing the same.
The applicant listed for this patent is NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO. LTD., SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION. Invention is credited to Chong-Pyoung Chung, In Ho Jo, Jue-Yeon Lee, Yoon Jeong Park, Yoon Shin Park, Jin Sook Suh.
Application Number | 20160296593 14/899607 |
Document ID | / |
Family ID | 55163353 |
Filed Date | 2016-10-13 |
United States Patent
Application |
20160296593 |
Kind Code |
A1 |
Chung; Chong-Pyoung ; et
al. |
October 13, 2016 |
NOVEL FAT ACCUMULATION INHIBITORY PEPTIDE AND PHARMACEUTICAL
COMPOSITION FOR PREVENTING OR TREATING OBESITY CONTAINING THE
SAME
Abstract
The present invention relates to a fat accumulation inhibitory
peptide which essentially comprises an amino acid sequence
represented by SEQ ID NO: 1, a pharmaceutical composition for
preventing or treating obesity, which contains the peptide, and a
health functional food for preventing or alleviating obesity, which
contains the peptide. The fat accumulation inhibitory peptide
according to the present invention has the function of inhibiting
the differentiation of mesenchymal stem cells into adipocytes to
thereby inhibit the accumulation of adipose tissue. Thus, the
peptide according to the present invention is highly useful for the
prevention or treatment of obesity.
Inventors: |
Chung; Chong-Pyoung; (Seoul,
KR) ; Park; Yoon Jeong; (Seoul, KR) ; Lee;
Jue-Yeon; (Gyeonggi-do, KR) ; Suh; Jin Sook;
(Seoul, KR) ; Jo; In Ho; (Chungcheongnam-do,
KR) ; Park; Yoon Shin; (Seoul, KR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO.
LTD. |
Seoul
Chungcheongbuk-do |
|
KR
KR |
|
|
Family ID: |
55163353 |
Appl. No.: |
14/899607 |
Filed: |
July 24, 2015 |
PCT Filed: |
July 24, 2015 |
PCT NO: |
PCT/KR2015/007707 |
371 Date: |
December 18, 2015 |
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A23V 2002/00 20130101;
C07K 7/06 20130101; A61P 3/04 20180101; A23L 33/18 20160801; A61P
3/00 20180101; A61K 38/08 20130101; C07K 14/001 20130101; A61K
38/16 20130101; A61K 9/0019 20130101; A23V 2002/00 20130101; A23V
2200/332 20130101 |
International
Class: |
A61K 38/16 20060101
A61K038/16; C07K 14/00 20060101 C07K014/00 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 24, 2014 |
KR |
10-2014-0094182 |
Claims
1. A fat accumulation inhibitory peptide which essentially
comprises an amino acid sequence represented by SEQ ID NO: 1.
2. The fat accumulation inhibitory peptide of claim 1, wherein the
fat accumulation inhibitory peptide consists of an amino acid
sequence represented by SEQ ID NO: 2.
3. The fat accumulation inhibitory peptide of claim 1, wherein the
peptide acts to inhibit the differentiation of mesenchymal stem
cells into adipocytes.
4. A pharmaceutical composition for preventing or treating obesity,
which contains the fat accumulation inhibitory peptide of claim
1.
5. The pharmaceutical composition of claim 4, wherein the obesity
is obesity caused estrogen deficiency.
6. The pharmaceutical composition of claim 4, wherein the
pharmaceutical composition further comprises a pharmaceutically
acceptable carrier.
7. The pharmaceutical composition of claim 6, wherein the
pharmaceutically acceptable carrier is at least one selected from
the group consisting of physiological saline, sterile water,
Ringer's solution, buffered saline, dextrose solution, maltodextrin
solution, glycerol, and ethanol.
8. The pharmaceutical composition of claim 4, wherein the
pharmaceutical composition further contains at least one additive
selected from the group consisting of an excipient, a buffer, an
antimicrobial preservative, a surfactant, an antioxidant, a
tonicity adjuster, a preservative, a thickener, and a viscosity
modifier.
9. The pharmaceutical composition of claim 4, wherein the
pharmaceutical composition is formulated for oral administration,
injection administration or in the form of a gelling agent for
local transplantation.
10. The pharmaceutical composition of claim 9, wherein the gelling
agent for local transplantation comprises a synthetic polymer or a
natural polymer.
11. The pharmaceutical composition of claim 10, wherein the
synthetic polymer is any one selected from the group consisting of
polylacticglycolic acid, poloxamer, and propylene glycol.
12. The pharmaceutical composition of claim 10, wherein the natural
polymer is any one selected from the group consisting of collagen,
alginic acid, propylene glycol alginic acid, chondroitin sulfate,
and chitosan.
13. The pharmaceutical composition of claim 4, wherein the fat
accumulation inhibitory peptide is administered in an amount of
1-60 mg per kg of body weight of a subject to be treated.
14. A health functional food for preventing or alleviating obesity,
which contains the fat accumulation inhibitory peptide of claim
1.
15. The health functional food of claim 14, wherein the obesity is
caused by estrogen deficiency.
Description
TECHNICAL FIELD
[0001] The present invention relates to a novel fat accumulation
inhibitory peptide, a pharmaceutical composition for preventing or
treating obesity, which contains the peptide, and a health
functional food for preventing or alleviating obesity, which
contains the peptide, and more particularly, to a fat accumulation
inhibitory peptide which essentially comprises an amino acid
sequence represented by SEQ ID NO: 1, a pharmaceutical composition
for preventing or treating obesity, which contains the peptide, and
a health functional food for preventing or alleviating obesity,
which contains the peptide.
BACKGROUND ART
[0002] Currently, the obese population is gradually increasing.
Obesity is a serious disease that causes diabetes, hyperlipidemia
and cardiovascular diseases leading to death. Obesity is a serious
health and social issue not only in advanced countries including
the USA, but also in Korea. In the USA, costs for treating obesity
account for about 6% of the total health-related costs, and in
Korea, the obesity treatment market size is approaching one
trillion Won (Korean currency). Obesity treatment agents are
representative quality-of-life (QOL) improvers together with
erectile dysfunction treatment agents and hair loss treatment
agents.
[0003] Obesity refers to a condition in which adipocytes in the
body proliferate and differentiate due to metabolic disorders, and
thus fat is excessively accumulated. If energy absorption is higher
than energy consumption, the number and volume of adipocytes
increase, resulting in an increase in the mass of adipose tissue
(Otto et al, Crit Rev Biochem Nol Biol., 40(4):229-242, 2005).
Obesity at the cellular level is understood as the increase in
number and volume of adipocytes caused by stimulation of the
proliferation and differentiation of adipocytes (Hirsch et al, Clin
Endocrinol Metab., 5(2):299-311, 1976).
[0004] Current methods for treating obesity include
drug-independent methods in which an excess of energy is consumed
through exercise. In methods of treating obesity with drugs, there
are used appetite suppressants that suppress appetite to limit
calorie uptake, lipase inhibitors, bulk laxatives, energy
stimulating agents, etc. The appetite suppressant sibutramine is a
drug that was originally used as an antidepressant, and exhibits
the effect of inhibiting the reuptake of serotonin in synapse to
thereby provide quick satiety. However, this drug was reported to
have various side effects, including cardiovascular action, central
action, hepatic disorders and renal disorders. Orlistat acts to
discharge fat from the body by inhibiting the function of the
digestive enzyme lipase that degrades fat to help the absorption of
fat in the body. However, Orlistat is known to have a serious side
effect such as fecal incontinence, and the effect thereof cannot be
guaranteed in the case of Koreans who live largely on
carbohydrates.
[0005] Particularly, in the case of women, estrogen levels are
lowered after the menopause while abdominal fat is accumulated. In
addition, the risk of complications such as type 2 diabetes,
cardiovascular diseases or osteoporosis also increases. Estrogen is
an important hormone that is secreted from the female ovary and is
involved in the development of uterine mucous membranes and mammary
glands, the appearance of female secondary sex characters, the
control of sexual cycles, and the maintenance of pregnancy. In
recent years, it was reported that female hormones are involved in
non-reproductive tissue (i.e., bone structure), cardiac blood
vessels (lipid metabolism), dementia, colon cancer, teeth, macular
degeneration, adipolysis, skin and collagen tissue production,
etc., and thus play a very important role in women' health. In the
case of hormone replace therapy (HRT) that was a potential
menopausal symptom relief therapy for a while, HRT has a high risk
of causing breast cancer, heart attack, stroke, cardiovascular
diseases, etc., when it is applied over a long period of time. For
this reason, the FDA announced to prohibit the long-term
administration of female hormone drugs.
[0006] Thus, there is an urgent need for a new obesity treatment
agent that cause less side effects and has guaranteed effects, and
the demand for this obesity treatment agent is continuously
increasing.
[0007] Accordingly, the present inventors have made extensive
efforts to solve the above-described problems occurring in the art.
As a result, the present inventors have developed a novel fat
accumulation inhibitory peptide which has the function of
inhibiting the differentiation of mesenchymal stem cells into
adipocytes to thereby inhibit the accumulation of adipose tissue,
similar to estrogen, and have found that the developed peptide has
the effect of preventing or treating obesity, thereby completing
the present invention.
DISCLOSURE OF INVENTION
[0008] It is an object of the present invention to provide a fat
accumulation inhibitory peptide which has the function of
inhibiting the differentiation of mesenchymal stem cells into
adipocytes to thereby inhibit the accumulation of adipose tissue,
similar to estrogen.
[0009] Another object of the present invention is to provide a
pharmaceutical composition for preventing or treating obesity, and
a health functional food for preventing or alleviating obesity,
which contain the above fat accumulation inhibitory peptide.
[0010] Still another object of the present invention is to provide
a method for preventing or treating obesity, which comprises
administering the above pharmaceutical composition containing the
fat accumulation inhibitory peptide.
[0011] Yet another object of the present invention is to provide
the use of the above pharmaceutical composition containing the fat
accumulation inhibitory peptide, for the prevention or treatment of
obesity.
[0012] To achieve the above objects, the present invention provides
a fat accumulation inhibitory peptide which essentially comprises
an amino acid sequence represented by SEQ ID NO: 1.
[0013] The present invention also provides a pharmaceutical
composition for preventing or treating obesity, and a health
functional food for preventing or alleviating obesity, which
contain the above fat accumulation inhibitory peptide.
[0014] The present invention also provides a method for preventing
or treating obesity, which comprises administering the above
pharmaceutical composition containing the fat accumulation
inhibitory peptide.
[0015] The present invention also provides the use of the above
pharmaceutical composition containing the fat accumulation
inhibitory peptide, for the prevention or treatment of obesity.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1 shows the inhibition of differentiation of
mesenchymal stem cells into adipocytes by the fat accumulation
inhibitory peptide according to the present invention.
Specifically, FIG. 1A is an image of adipocytes stained with Oil
Red O, and FIG. 1B shows the absorbance of free Oil Red O.
[0017] FIG. 2 shows the inhibition of differentiation of
mesenchymal stem cells into adipocytes by the fat accumulation
inhibitory peptide according to the present invention, and shows
the results of electrophoresis of PCR products obtained in Example
2.
[0018] FIG. 3 shows the results of measuring the change in body
weight caused by the fat accumulation inhibitory peptide according
to the present invention, in Example 3.
[0019] FIG. 4 shows the results of measuring the change in total
fat weight caused by the fat accumulation inhibitory peptide
according to the present invention, in Example 3.
[0020] FIG. 5 shows the results of measuring the change in total
fat/body weight caused by the fat accumulation inhibitory peptide
according to the present invention, in Example 3.
[0021] FIG. 6 shows the results of measuring the change in
subcutaneous fat weight caused by the fat accumulation inhibitory
peptide according to the present invention, in Example 3.
[0022] FIG. 7 shows the results of measuring the change in
subcutaneous fat/body weight caused by the fat accumulation
inhibitory peptide according to the present invention, in Example
3.
[0023] FIG. 8 shows the results of measuring the change in
liver/body weight caused by the fat accumulation inhibitory peptide
according to the present invention, in Example 3.
[0024] FIG. 9 shows the results of measuring the change in
kidney/body weight caused by the fat accumulation inhibitory
peptide according to the present invention, in Example 3.
BEST MODE FOR CARRYING OUT THE INVENTION
[0025] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which the invention pertains.
Generally, the nomenclature used herein and the experiment methods,
which will be described below, are those well known and commonly
employed in the art.
[0026] In the present invention, a novel fat accumulation
inhibitory peptide was prepared, and mice were treated with the
prepared peptide in order to examine the effects of the peptide on
the inhibition of adiopocyte differentiation and fat accumulation.
As a result, it was found that the fat accumulation inhibitory
peptide has the effect of inhibiting fat accumulation, and thus can
be used as an obesity treatment agent.
[0027] In one aspect, the present invention is directed to a fat
accumulation inhibitory peptide which essentially comprises an
amino acid sequence represented by the following SEQ ID NO: 1:
TABLE-US-00001 SEQ ID NO 1: YGLRSKS
[0028] In the present invention, the fat accumulation inhibitory
peptide may comprise an amino acid sequence represented by the
following SEQ ID NO 2:
TABLE-US-00002 SEQ ID NO 2: YGLRSKSKKFRRPDIQYPDAT.
[0029] In the present invention, the fat accumulation inhibitory
peptide may act to inhibit the differentiation of mesenchymal stem
cells into adipocytes.
[0030] In another aspect, the present invention is directed to a
pharmaceutical composition for preventing or treating obesity,
which contain the above fat accumulation inhibitory peptide.
[0031] In still another aspect, the present invention is directed
to a method for preventing or treating obesity, which comprises
administering the above pharmaceutical composition containing the
fat accumulation inhibitory peptide.
[0032] In yet another aspect, the present invention is directed to
the use of the above pharmaceutical composition containing the fat
accumulation inhibitory peptide, for the prevention or treatment of
obesity.
[0033] As used herein, the term "composition" is intended to
include not only a product containing a specific component but also
any product made directly or indirectly by the combination of a
specific component.
[0034] In the present invention, obesity may be caused by estrogen
deficiency.
[0035] In the present invention, the pharmaceutical composition may
further comprise a pharmaceutically acceptable carrier. The carrier
pharmaceutically acceptable may be at least one selected from the
group consisting of physiological saline, sterile water, Ringer's
solution, buffered saline, dextrose solution, maltodextrin
solution, glycerol, and ethanol, but is not limited thereto.
[0036] In the present invention, the pharmaceutical composition may
further contain at least one additive selected from the group
consisting of an excipient, a buffer, an antimicrobial
preservative, a surfactant, an antioxidant, a tonicity adjuster, a
preservative, a thickener, and a viscosity modifier, but is not
limited thereto.
[0037] In the present invention, the pharmaceutical composition may
be formulated for oral administration, injection administration or
in the form of a gelling agent for local transplantation, but is
not limited thereto. The composition of the present invention may
be prepared into a suitable formulation using a known technique
(Joseph Price Remington, Remington's Pharmaceutical Science, 17th
edition, Mack Publishing Company, Easton, Pa.).
[0038] The pharmaceutical composition for preventing or treating
obesity according to the present invention can be administered
through routes that are usually used in the medical field. The
composition of the present invention is preferably administered
parenterally. The composition according to the present invention
may be administered, for example, orally, intravenously,
intramuscularly, intraarterially, intramedullarily, intradually,
intracardially, transdermally, subcutaneously, intraperitoneally,
intrarectally, sublingually or topically.
[0039] In the present invention, the gelling agent for local
transplantation comprises a synthetic polymer such as
polylacticglycolic acid, poloxamer or propylene glycol, or a
natural polymer such as collagen, alginic acid, propylene glycol
alginic acid, chondroitin sulfate or chitosan, but is not limited
to thereto.
[0040] The dose of the pharmaceutical composition for preventing or
treating obesity according to the present invention may vary
depending on the patient's weight, age, sex, health condition and
diet, the time of administration, the mode of administration,
excretion rate, the severity of the disease, or the like, and can
be easily determined by those skilled in the art in consideration
of the above factors.
[0041] The pharmaceutical composition of the present invention may
be administered as an individual therapeutic agent or in
combination with other therapeutic agents, and may be administered
sequentially or simultaneously with conventional therapeutic
agents.
[0042] In the present invention, the fat accumulation inhibitory
peptide may be administered in an amount of preferably 1-60 mg,
more preferably 3-30 mg, per kg of body weight of a subject to be
treated.
[0043] In a further aspect, the present invention is directed to a
health functional food for preventing or alleviating obesity, which
contains the above fat accumulation inhibitory peptide.
[0044] As used herein, the term "health functional food" refers to
a food is prepared and processed from raw materials or components
having functionality useful for the human body pursuant to the law
No. 6722 on the health functional food, or refers to a food that is
taken for the purpose of controlling nutrients with respect to the
structure and function of the human body or obtaining the effects
useful for the health purposes such as physiologically functional
purpose.
[0045] The health functional food according to the present
invention may be formulated into a typical health functional food
preparation known in the art. The health functional food may be
prepared in the form of granules, tablets, pills, suspensions,
emulsions, syrups, chewing gums, teas, jellies, various beverages,
drinks, alcoholic beverages or the like. There is no particular
limitation in the kind of the health functional food.
[0046] The health functional food according to the present
invention may be any suitable galenical form for administration to
the animal body including the human body, more specifically, any
conventional form for oral administration, for example, food or
feed, food or feed additives and adjuvants, enhanced food or feed,
a solid form such as tablets, pills, granules, capsules and foam
formulations, or a liquid form such as solutions, suspensions,
emulsions, drinks and pastes. The composition of the present
invention may contain nutrients, vitamins, electrolytes,
sweeteners, colorants, organic acids, preservatives, etc. These
additives may be used independently or in combination.
EXAMPLES
[0047] Hereinafter, the present invention will be described in
further detail with reference to examples. It will be obvious to a
person having ordinary skill in the art that these examples are
illustrative purposes only and are not to be construed to limit the
scope of the present invention.
Example 1
Synthesis of Fat Accumulation Inhibitory Peptide
[0048] A peptide represented by the following SEQ ID NO: 2 was
synthesized from the C-terminus by an F-moc solid phase chemical
synthesis method using a peptide synthesizer:
TABLE-US-00003 SEQ ID NO 2: YGLRSKSKKFRRPDIQYPDAT
[0049] The synthesized peptide sequence was separated from resin,
washed, freeze-dried, and then purified by liquid chromatography.
The molecular weight of the purified peptide was analyzed by
MALDI.
Example 2
Adipocyte Differentiation Inhibitory Effect of Fat Accumulation
Inhibitory Peptide
[0050] Using mesenchymal stem cells (MSCs), the effect of the fat
accumulation inhibitory peptide, prepared in Example 1, on
adipocyte differentiation, was studied.
[0051] Mesenchymal stem cells (MSCs) were cultured in DMEM
containing 1% antibiotic-antimycotic and 10% FBS, and were stored.
Next, the cells were cultured in adipocyte differentiation
induction medium (DMEM containing 10% FBS, 10 .mu.M dexamethasone,
0.5 mM methyl-isobutylxanthine, 10 .mu.g/ml insulin, 10 mM
indomethacin, and 1% antibiotic-antimycotic) for 3 days, and were
cultured in adipocyte differentiation induction medium (DMEM
containing 10 .mu.g/ml insulin, 10% FBS, and 1%
antibiotic-antimycotic) for 3 days. The cells were culture for 14
days while the medium was replaced in the above order, thereby
inducing differentiation of the cells. During the culture, a
mixture of 95% air and 5% CO.sub.2 was continuously supplied while
a humidity of 100% and a temperature of 37.degree. C. were
maintained. The culture for differentiation was performed for a
total of 14 days, and the peptide prepared in Example 1 was added
whenever the medium was replaced. The peptide was added at
concentrations of 0, 10, 100 and 200 .mu.g/mL.
[0052] The cells cultured in the differentiation medium were washed
with PBS and fixed with 10% formalin for 1 hour. 30% Oil red O
solution diluted with 60% isopropanol was added to the cells which
were then incubated at room temperature for 10 minutes. The cells
were washed with purified water and observed with an optical
microscope. After observation, isopropanol was added to dissolve
the formed fat, and the absorbance at 510 nm was measured.
[0053] As a result, it could be seen that the differentiation of
the mesenchymal stem cells into adipocytes was increased by the
adipocyte differentiation medium (FIG. 1). In addition, it could be
microscopically observed that, as the concentration of the peptide
used to treat the cells increased, the accumulation of the fat
stained with Oil red O decreased (FIG. 1A). Furthermore, when the
produced fat was dissolved and the absorbance at 510 nm was
measured, it could be seen that, as the concentration of the
peptide increased, the absorbance decreased (FIG. 1B).
[0054] In addition, in the same manner as described above,
mesenchymal stem cells were treated with the peptide prepared in
Example 1. RNA was extracted from the cells and subjected to
reverse transcription polymerase chain reaction (RT-PCR) using
primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) which
is a control, and adipocyte protein 2 (aP2) and peroxisome
proliferators activated receptor .gamma. (PPAR.gamma.), which are
adipocyte differentiation markers. The PCR products were
electrophoresed on agarose gel in order to compare the expression
levels of the control and the differentiation markers.
[0055] As a result, it could be seen that, as the concentration of
the peptide used to treat the cells increased, the expression of
the control GAPDH gene did not change, but the expression of the
adipocyte differentiation marker genes (aP2 and PPAR.gamma.)
decreased (FIG. 2).
Example 3
Fat Accumulation Inhibitory and Toxic Effects of Fat Accumulation
Inhibitory Peptide
[0056] ICR mice (Orient Bio, Korea) were purchased and acclimated,
and the ovary was removed from the mice to induce estrogen
deficiency, thereby inducing bone loss and an increase in the body
weight of the mice. For ovariectomy, 6-week-old ICR mice were
generally anesthetized by intramuscularly injecting a mixture of 10
mg/kg of xylazine (Rompun.RTM., Bayer, Korea) and 100 mg/kg of
ketamine (Ketalar.RTM., Yuhan Corp., Korea) into the femoral region
of the mice. The ovary present below both kidneys was carefully
removed, and the mice were sutured according to a conventional
method and injected intramuscularly with 3 mg/kg of gentamicin
(Gentamicin.RTM., Choongwae Pharma Corp., Korea), and then kept.
From 3 months after ovariectomy, the peptide prepared in Example 1
was administered intraabdominally to the mice twice a week for a
total of 8 weeks. The test animals were divided into 7 test groups
as shown in Table 1 below, and the change in body weight and the
fat accumulation of the mice were measured.
TABLE-US-00004 TABLE 1 Division of Test Animals Sham Sham (Pseudo-
(Pseudo- OVX Normal OVX)-PBS OVX)-HP Control LP HP Treatment
materials PBS PBS Peptide of PBS Peptide of Peptide of
(concentration, .mu.g/25 g SEQ ID SEQ ID SEQ ID mice) NO: 2 NO: 2
NO: 2 (600 .mu.g) (60 .mu.g) (600 .mu.g) Number (heads) 10 5 5 10
10 10 [Normal: normal group; Sham (Pseudo-OVX): non-ovariectomized
test group; OVX: ovariectomized test group; Control: control group;
LP: low-concentration peptide (60 .mu.g/25 g mouse); HP:
high-concentration peptide (600 .mu.g/25 g mouse)]
[0057] When the change in the body weight of the mice was observed,
it could be seen that the body weight and total fat weight of the
ovariectomized test group increased and that the OVX-PBS group
showed a significant increase in the body weight compared to the
normal group. In addition, it could be seen that the total fat
weight and the total fat/body weight were significantly higher in
the OVX-PBS group than in the normal group, but significantly
decreased in the test group treated with the peptide, suggesting
that the peptide inhibits fat accumulation (FIGS. 3 to 5).
[0058] When the change in subcutaneous fat weight of the mice was
observed, it could be seen that the subcutaneous fat weight changed
more greatly than the total fat weight. Also, it could be seen
that, in the ovariectomized test group, the subcutaneous fat weight
significantly increased, but in the test group treated with the
peptide, the subcutaneous fat weight decreased (FIGS. 6 and 7).
[0059] In addition, as the indices of the hepatotoxicity and
nephrotoxicity of the peptide, the weights of the liver and kidney
of the mice were measured after autopsy. As a result, it could be
seen that the weights of liver and kidney/body weight of the test
group treated with the peptide were all similar to those of the
normal group, suggesting that the hepatotoxicity and nephrotoxicity
of the peptide were insignificant (FIGS. 8 and 9).
INDUSTRIAL APPLICABILITY
[0060] As described above, the fat accumulation inhibitory peptide
according to the present invention has the function of inhibiting
the differentiation of mesenchymal stem cells into adipocytes to
thereby inhibit the accumulation of adipose tissue, similar to
estrogen. Thus, the peptide according to the present invention is
highly useful for the prevention or treatment of obesity.
[0061] Although the present invention has been described in detail
with reference to the specific features, it will be apparent to
those skilled in the art that this description is only for a
preferred embodiment and does not limit the scope of the present
invention. Thus, the substantial scope of the present invention
will be defined by the appended claims and equivalents thereof.
Sequence CWU 1
1
217PRTArtificial Sequencepeptide for inhibiting fat accumulation
1Tyr Gly Leu Arg Ser Lys Ser 1 5 221PRTArtificial Sequencepeptide
for inhibiting fat accumulation 2Tyr Gly Leu Arg Ser Lys Ser Lys
Lys Phe Arg Arg Pro Asp Ile Gln 1 5 10 15 Tyr Pro Asp Ala Thr
20
* * * * *